Condition

B-cell Non Hodgkin Lymphoma clinical trials and research

• 29Clinical trials
• 24Countries

Newest B-cell Non Hodgkin Lymphoma clinical trials

All recruiting trials (29)

• GI001 CAR-T for relapsed or refractory B-cell NHL and B-ALL

  This treatment study tests GI001, an in vivo CAR-T therapy, to see if it is safe and helpful for adults with relapsed or refractory B-cell NHL or B-ALL.

  Recruiting Early Phase 1 Hematology department of the 920th hospital · Yunnan, Kunming · NCT07862010

• ARC-02 with Rituximab for B-cell non-Hodgkin lymphomas

  This study tests ARC-02, together with Rituximab, to see if the treatment is safe and shows early signs of activity in people with B-cell non-Hodgkin lymphomas who have already tried multiple therapies.

  Recruiting at 3 sites Phase 1 Taiho Oncology, Inc. · Los Angeles, California and 27 other locations · NCT07691606

• SHR-3079 in B-cell non-Hodgkin lymphoma

  This small early study tests SHR-3079 in adults with B-cell non-Hodgkin lymphoma to see if it is safe and tolerable and to find a workable dose for future testing.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07661537

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• First-in-human test of DS3790a for hematological malignancies

  This first-in-human trial will test DS3790a alone and with other drugs to see if it's safe, how it behaves in the body, and whether it helps adults with hematological malignancies.

  Recruiting at 8 sites Phase 1/2 Daiichi Sankyo · New York, New York and 7 other locations · NCT07220616

• AZD4512 alone or with other medicines for relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial will try AZD4512 by itself or with other cancer drugs to see if it helps adults whose B‑cell non‑Hodgkin lymphoma has relapsed or not responded after prior treatments.

  Recruiting at 16 sites Phase 1/2 AstraZeneca · Irvine, California and 22 other locations · NCT07123454

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• mRNA therapy that makes a CD19/CD3 T-cell engager (ABO2203) for relapsed or refractory B-cell non-Hodgkin lymphoma.

  This will try an mRNA drug (ABO2203) that makes immune-engaging CD19/CD3 proteins to see if it is safe and helps adults with relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma.

  Recruiting Phase 1 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07072169

• CT1190B CAR‑T therapy for relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial will test CT1190B CAR‑T cell therapy in adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma to see if it is safe and can shrink disease.

  Recruiting Phase 1 Tongji Hospital · Wuhang, Hubei · NCT07053670

• Evaluating a new CAR T-cell therapy for patients with relapsed B-cell cancers

  This study is testing a new CAR T-cell therapy to see if it can help adults with relapsed B-cell cancers like leukemia and lymphoma feel better and live longer.

  Recruiting Phase 1 University of Kansas Medical Center · Westwood, Kansas · NCT06879340

• Exploring CT1190B for treating relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new CAR-T cell therapy called CT1190B to see if it can safely help people with relapsed B-cell Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06822868

• Exploring CT1190B for treating relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new CAR-T cell therapy called CT1190B to see if it can safely help people with relapsed B-cell Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Shanghai Tongji Hospital, Tongji University School of Medicine · Shanghai, Shanghai Municipality · NCT06734871

• Evaluating JMT601 for treating relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma

  This study is testing a new treatment called JMT601 to see if it can help people with relapsed or hard-to-treat CD20-positive B-cell non-Hodgkin lymphoma feel better and stay safe during the process.

  Recruiting Phase 1 Shanghai JMT-Bio Inc. · Shanghai · NCT06725524

• Using cord blood-derived CAR NK cells to treat refractory B-cell lymphoma

  This study is testing a new treatment using special immune cells from cord blood to see if it can help people with hard-to-treat B-cell lymphoma feel better.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06707259

• Evaluating AZD0486 for treating mature B-cell cancers

  This study is testing a new treatment called AZD0486 to see if it can help people with certain types of mature B-cell cancers feel better and improve their health.

  Recruiting at 56 sites Phase 1/2 AstraZeneca · Boston, Massachusetts and 65 other locations · NCT06564038

• Treatment with AZD0486 for patients with relapsed B-cell lymphoma

  This study is testing a new treatment called AZD0486 to see if it can help adults with relapsed B-cell lymphoma feel better and stay safe after trying other therapies.

  Recruiting at 80 sites Phase 2 AstraZeneca · Phoenix, Arizona and 93 other locations · NCT06526793

• Long-term follow-up for patients treated with Miltenyi CAR T therapies

  This study looks at how well Miltenyi CAR T cell therapies work and their long-term safety for patients, especially kids, who have already been treated.

  Recruiting at 2 sites Miltenyi Biomedicine GmbH · Berlin and 6 other locations · NCT06508775

• Evaluating DR-0201 for patients with relapsed B-cell Non-Hodgkin Lymphoma

  This study is testing a new treatment called DR-0201 to see if it can help adults with relapsed B-cell non-Hodgkin lymphoma who have already tried other therapies.

  Recruiting at 15 sites Phase 1 Sanofi · Camperdown, New South Wales and 15 other locations · NCT06392477

• CAR-T therapy after stem cell transplant for relapsed B-cell lymphoma

  This study is testing if a new CAR-T therapy can help people with relapsed B-cell lymphoma feel better after they’ve had a stem cell transplant.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT06365671

• Treatment using modified T-cells for relapsed or refractory B-cell cancers

  This study is testing a new treatment that uses specially modified T-cells to see if it can help people with hard-to-treat B-cell cancers.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06191887

• Geriatric assessment to improve recovery after CAR-T therapy for older patients with blood cancers

  This study is testing if personalized support and therapy can help older patients with blood cancers recover better after receiving CAR-T treatment.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 3 other locations · NCT06052826

• New treatments for children and young people with hard-to-treat B-cell lymphoma

  This study is testing new medications for children and teens with hard-to-treat B-cell lymphoma to see if they can improve their treatment outcomes.

  Recruiting at 6 sites Phase 2/3 University of Birmingham · Sydney, New South Wales and 10 other locations · NCT05991388

• Metabolically enhanced CAR T-cell therapy for relapsed B-cell cancers

  This study is testing a new way to improve CAR T-cell therapy for patients with relapsed B-cell cancers to see if it can work better and be safer.

  Recruiting Phase 1/2 Medical University of South Carolina · Charleston, South Carolina · NCT05702853

• Using cord blood-derived CAR-NK cells to treat B-cell non-Hodgkin lymphoma

  This study is testing a new treatment using special immune cells from cord blood to see if it can help people with tough-to-treat B-cell non-Hodgkin lymphoma feel better.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT05472558

• Using genetically modified T-cells and a vaccine to treat certain types of B-cell lymphoma after stem cell transplantation

  This study is testing a new treatment using specially modified immune cells and a vaccine to see if it can help people with certain types of B-cell lymphoma after they've had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05432635

• IKS03 treatment for advanced B cell non-Hodgkin lymphomas

  This study is testing a new treatment called IKS03 for people with advanced B cell non-Hodgkin lymphoma to see how safe and effective it is.

  Recruiting at 12 sites Phase 1 Iksuda Therapeutics Ltd. · Baltimore, Maryland and 12 other locations · NCT05365659

• Evaluating AT101 for patients with relapsed B-cell Non-Hodgkin's Lymphoma

  This study is testing a new treatment called AT101 to see if it can help people with relapsed B-cell non-Hodgkin's lymphoma feel better and how safe it is.

  Recruiting Phase 1/2 AbClon · Seoul · NCT05338931

• New CAR-T therapy for pediatric B-cell leukemia and lymphoma

  This study is testing a new CAR-T therapy for children with tough-to-treat B-cell leukemia and lymphoma to see if it can help them get better and have more treatment options.

  Recruiting Phase 1/2 University of Colorado, Denver · Aurora, Colorado · NCT04544592

• Vaccine treatment for relapsed or refractory blood cancers

  This study is testing a new vaccine treatment for people with relapsed or hard-to-treat blood cancers to see if it can help them feel better and live longer.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT03017820

Related topics

Quick answers

How many B-cell Non Hodgkin Lymphoma clinical trials are recruiting right now?

29, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in United States (15 trials), China (13 trials), Australia (7 trials), Italy (6 trials), South Korea (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 16, Phase 1/2: 6, Phase 2: 4, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →